Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

Solid Tumors Clinical Trial

Official title:

A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00044785
• Other study ID #: 401.02.001
• Secondary ID: GCC0121
• Status: Terminated
• Phase: Phase 1
• First received: September 4, 2002
• Last updated: June 23, 2005
• Start date: August 2002
• Est. completion date: March 2004

Study information

• Verified date: May 2005
• Source: Wellstat Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU, leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well tolerated and therefore potentially increase effectiveness.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 24
• Est. completion date: March 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Must be at least 18 years of age;

• Life expectancy: At least 3 months;

• Performance status: ECOG of 0 or 1;

• Histologic or cytologic proof of a solid tumor cancer that is not amenable to curative surgical resection;

• Evaluable or measurable disease documented within 4 weeks of the start of treatment;

• Prior chemotherapy or radiotherapy is allowed if 4 weeks or more have elapsed prior to starting treatment and patients have recovered from toxicities of prior treatment;

• Adequate organ function:

Hematopoietic: ANC = 1500/ul or more, Platelets = 100,000/ul or more, Hemoglobin = 9.5 g/dL or more, transfusion prior to evaluation is allowed; Hepatic: Bilirubin = 2.0 mg/dL or less and SGPT(ALT) and SGOT(AST) < 3 x upper limit of normal (< 5 x upper limit of normal if liver metastases present) Renal: Serum Creatinine < 2.0 mg/dL;

• Patient has the initiative, geographic proximity, and means to be compliant with the protocol;

• Fertile patients (male or female) must agree to use effective contraception;

• Must be able to swallow and retain tablets.

Exclusion Criteria

• Major surgery within the four weeks preceding the start of treatment;

• Serious medical or psychiatric illness that would prevent self-determined informed consent;

• Intensive chemotherapy treatment;

• Infection or antibiotics at the time of screening;

• Uncontrolled cardiovascular, pulmonary, renal, neurologic, psychiatric, or hepatic dysfunction;

• Pregnant or nursing;

• Pre-existing diarrhea or uncontrolled clinically significant illness other than cancer (i.e. ulcerative colitis, malabsorption syndrome);

• Brain metastases that have not been stable for more than 3 months;

• Known Dihydropyrimidine Dehydrogenase (DPD) deficiency.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• triacetyluridine

• fluorouracil

• leucovorin

• camptosar

Locations

Country	Name	City	State
United States	University of Maryland, Greenebaum Cancer Center	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Wellstat Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Maximum Tolerated Dose